The agreement provides access for prescribed patients to Lilly's obesity medicines self-pay pricing starting at $149 per month without leaving the platform.
News|Articles|September 1, 2026
5 Essential Capabilities for Decentralized Clinical Trials
Author(s)Quest Diagnostics
Advertisement
As the clinical research landscape evolves, decentralized clinical trials (DCTs) have emerged as a foundational competency, enabling broader patient participation, increasing trial efficiency, and driving more inclusive, real-world data collection. However, the successful execution of DCTs requires more than just innovative technology—it demands a comprehensive strategy that addresses the unique challenges of decentralization.
Advertisement
Related to this article
Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
Brox.AI’s Hamish Brocklebank on three levels of digital clone use cases — from HCP content testing and GLP-1 price sensitivity modeling to simulating physician adoption after FDA approval.
Brox.AI’s Hamish Brocklebank on the three approaches to digital twins in pharma — and why only one-to-one clones of real individuals deliver true accuracy.
Advertisement
Advertisement
Trending on PharmExec
1
The US Drug-Pricing Reset: Competing on Net Value
2
Novo Terminates Research Collaboration With Korro Bio
3
Pharmaceutical Executive Daily: FDA Grants Accelerated Approval to Rybrevant Faspro
4
Hims & Hers Partners with Eli Lilly to Sell Obesity Medicines
5